Name: "If it Isn't A.I., It's Weight Loss": Eli Lilly (LLY) Rallies on Earnings
Uploaded: 2024-08-08T14:53:32.845-05:00
Duration: 2 min 37 s
Description: James Demmert joins Oliver Renick and Tom White to discuss Eli Lilly's (LLY) 2Q earnings beat, the impact of GLP-1 drugs and the outlook for the health care sector.

Morning Movers

Opening Bell With Nicole Petallides

Morning Trade Live

Trading 360

Fast Market

Next Gen Investing

The Watch List

Market On Close

Market Overtime

Inside the Mind of a Trader

Your First Trade

The Wrap

Liz Ann Live

Schwab 2026 Outlook

<p>Sam Vadas takes traders beyond the headlines with a sharp focus on the macro drivers, sector rotations, and global forces shaping the day’s market action. From breaking down U.S. and international economic data to analyzing sector performance and cross-asset moves, Morning Trade Live delivers the context traders need to understand the “why” behind early trading activity.</p>

Daily insights for every investor

Schwab Network's Newsletters

<p>James Demmert joins Oliver Renick and Tom White to discuss Eli Lilly's (LLY) 2Q earnings beat, the impact of GLP-1 drugs and the outlook for the health care sector.</p>

"If it Isn't A.I., It's Weight Loss": Eli Lilly (LLY) Rallies on Earnings

Expert commentary about top moving stocks, sectors, and commodities, along with CEO and analyst interviews.

Market News